Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, Spotbeen X, Bagadi M, Waltregny D, Moldovan M, Dehairs J, Vanderhoydonc F, Bloch K, Das R, Stahl J, Kench JG, Gevaert T, Derua R, Waelkens E, Nassar ZD, Selth LA, Trim PJ, Snel MF, Lynn DJ, Tilley WD, Horvath LG, Centenera MM, Swinnen JV. Butler LM, et al. Cancer Res. 2021 Oct 1;81(19):4981-4993. doi: 10.1158/0008-5472.CAN-20-3863. Epub 2021 Aug 6. Cancer Res. 2021. PMID: 34362796
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD. Buchanan G, et al. Among authors: butler lm. Cancer Res. 2005 Sep 15;65(18):8487-96. doi: 10.1158/0008-5472.CAN-04-3077. Cancer Res. 2005. PMID: 16166329 Free article.
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM. Marrocco DL, et al. Among authors: butler lm. Mol Cancer Ther. 2007 Jan;6(1):51-60. doi: 10.1158/1535-7163.MCT-06-0144. Epub 2007 Jan 11. Mol Cancer Ther. 2007. PMID: 17218635
351 results